Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

about

Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation.

P2860

Q39319162-A3C8FDE7-059E-4C98-8392-33C938E963D7 Q54937207-5D1BE83B-8A0A-47BE-AD21-EB8DB6E13EED

P2860

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Item

http://www.wikidata.org/entity/Q39316588

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Cessation of targeted therapy ...... anced melanoma: a case series.

@en

Cessation of targeted therapy ...... anced melanoma: a case series.

@nl

type

Item

label

Cessation of targeted therapy ...... anced melanoma: a case series.

@en

Cessation of targeted therapy ...... anced melanoma: a case series.

@nl

prefLabel

Cessation of targeted therapy ...... anced melanoma: a case series.

@en

Cessation of targeted therapy ...... anced melanoma: a case series.

@nl

P1476

Cessation of targeted therapy ...... anced melanoma: a case series.

@en

P2093

Alex Guminski

http://www.w3.org/2001/XMLSchema#string

Christina Girgis

http://www.w3.org/2001/XMLSchema#string

Lucia Festino

http://www.w3.org/2001/XMLSchema#string

Matteo S Carlino

http://www.w3.org/2001/XMLSchema#string

Vito Vanella

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.

P2888

bjc.2016.321

P304

1280-1284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2016.321

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Antonio Ascierto

P577

2016-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024818226

http://www.w3.org/2001/XMLSchema#string

P698

27711085

http://www.w3.org/2001/XMLSchema#string

P932

5129828

http://www.w3.org/2001/XMLSchema#string

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

about

P2860

P2860

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932